{"id":379649,"date":"2020-11-12T08:15:29","date_gmt":"2020-11-12T13:15:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379649"},"modified":"2020-11-12T08:15:29","modified_gmt":"2020-11-12T13:15:29","slug":"effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/","title":{"rendered":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada. The study [<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-bI7SOMxN-d7bNLYrOo3nD8e30Rx-dZ0d1eCTkbJeY4dq3UekNXZ6nfPFwyNRgQ6pkSDS12heTSDOU0mcBLtQtdwYEPDet8EyzCvHfqUa3Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NCT04261218<\/a>] is funded through Stand Up To Cancer (SU2C) Canada. Tomivosertib is an oral, small molecule inhibitor of MNK1\/2 that enhances T cell killing of tumors, delays T cell exhaustion and enhances T cell memory. Paclitaxel is a chemotherapy agent used to treat multiple tumor types, including breast cancer.\u00a0<\/p>\n<p>This Canadian study is led by Nahum Sonenberg, Ph.D., professor and Gillman Cheney Chair in biochemistry at McGill University in Montreal and a world-renowned expert in translation, and Michael Pollack, M.D., Alexander Goldfarb Research Chair in cancer research at McGill University. The Phase 2 open-label study will enroll approximately 40 patients with metastatic breast cancer for whom the standard of care has been ineffective. The study will evaluate the safety and pharmacodynamics of tomivosertib. Secondary outcomes measures include efficacy, as well as numerous biomarkers that explore the effect of tomivosertib on immune function and oncogene expression.<\/p>\n<p>\n        <strong>About Tomivosertib (eFT508)<\/strong><br \/>\n        <br \/>Tomivosertib is eFFECTOR\u2019s wholly-owned, highly selective translation regulation inhibitor that targets MNK1 and MNK2 (MNK1\/2). The oral, small molecule drug candidate has been shown to enhance T cell killing, delay T cell exhaustion and enhance the T cell central memory pool. Tomivosertib is expected to enter KICKSTART, eFFECTOR\u2019s randomized, placebo-controlled, double-blind Phase 2 study in non-small lung cancer (NSCLC) in combination with pembrolizumab, in Q4 2020. The KICKSTART study builds on results obtained in an earlier study of tomivosertib as an extension of checkpoint inhibitor treatment in patients experiencing insufficient response to an FDA-approved checkpoint inhibitor alone [<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n0PSwq2b3ngfyFqLuPH7YITt1_MfQKNYfwDuiLvnjv2632EuIseZZTcCr3jZjjkE9QYRjjWXQy_Q5rEnbT8z1onsqnITFc0IjfRwPT_sTKtIAYFR79He8VLAk7SxFyahx5SaF2QrF6EKB067TYuNEEQPZrwbU9_xouphtauidgvtVp0xK_70gd2dxwUiP5ZwlF6V3gcok9-ztn-4cHoata7JXij1utcxSKjAI-dYS1l5WjiL8Y_XwcY-pw_kAdkt\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NCT03616834<\/a>].<\/p>\n<p>Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6aGe2SQdD9tMB42bK2fpsdobWGI6mFuoAu9cBtyMuCpDhlhD642pxO1EOE328fG2tyfZ8_yz-aoD3a8aqqg_e2iZArFNMUdGc-CjPj7DDHY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.clinicaltrials.gov<\/a> for further information on ongoing clinical studies of tomivosertib.<\/p>\n<p>\n        <strong>About eFFECTOR<\/strong>\n      <\/p>\n<p>eFFECTOR is a next-generation oncology company developing a new class of targeted therapies called selective translation regulator inhibitors (STRIs). Tomivosertib, eFFECTOR\u2019s MNK1\/2 inhibitor is expected to enter KICKSTART, a randomized Phase 2 trial in non-small cell lung cancer (NSCLC) in combination with pembrolizumab, in Q4 2020. Zotatifin, eFFECTOR\u2019s inhibitor of eIF4A, is in a dose-escalation Phase 1 trial, with expansion cohorts expected to open in H1 2021. eFFECTOR has a partnership with Pfizer developing inhibitors of eIF4E.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Amy Conrad<br \/>Juniper Point<br \/>858-366-3243<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V6-BiPEmRk7c9fnqrjPu9LwX2p9pVebKabYr1YSld7ujGDXqHNJiSYUmzvaTCFAHCQdl-ZMs7GuBaxkIuuSgv8MF38ybkUxQvgZL12lCOz4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">amy@juniper-point.com<\/a><\/u><br \/>\u00a0\u00a0 <br \/><strong>Media:<\/strong><br \/>Heidi Chokeir, Ph.D.<br \/>Canale Communications<br \/>619-849-5377<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fmbF1vxLjdfw8pEJQh6zsG8F2gYxKzIFIn2G62OHzlqobozeqTpbY6mPenLxpeJQMkRkYUlZ20B_kR-3_eLa0UTGjHjjle7YPULWpDmOsZl9ynI06Bw6rogfC-xksxKr\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">heidi.chokeir@canalecomm.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada. The study [NCT04261218] is funded through Stand Up To Cancer (SU2C) Canada. Tomivosertib is an oral, small molecule inhibitor of MNK1\/2 that enhances T cell killing of tumors, delays T cell exhaustion and enhances T cell memory. Paclitaxel is a chemotherapy agent used to treat multiple tumor types, including breast cancer.\u00a0 This Canadian study is led by Nahum Sonenberg, Ph.D., professor and Gillman Cheney &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379649","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada. The study [NCT04261218] is funded through Stand Up To Cancer (SU2C) Canada. Tomivosertib is an oral, small molecule inhibitor of MNK1\/2 that enhances T cell killing of tumors, delays T cell exhaustion and enhances T cell memory. Paclitaxel is a chemotherapy agent used to treat multiple tumor types, including breast cancer.\u00a0 This Canadian study is led by Nahum Sonenberg, Ph.D., professor and Gillman Cheney &hellip; Continue reading &quot;eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T13:15:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada\",\"datePublished\":\"2020-11-12T13:15:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/\"},\"wordCount\":443,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/\",\"name\":\"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\",\"datePublished\":\"2020-11-12T13:15:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/","og_locale":"en_US","og_type":"article","og_title":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk","og_description":"SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada. The study [NCT04261218] is funded through Stand Up To Cancer (SU2C) Canada. Tomivosertib is an oral, small molecule inhibitor of MNK1\/2 that enhances T cell killing of tumors, delays T cell exhaustion and enhances T cell memory. Paclitaxel is a chemotherapy agent used to treat multiple tumor types, including breast cancer.\u00a0 This Canadian study is led by Nahum Sonenberg, Ph.D., professor and Gillman Cheney &hellip; Continue reading \"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T13:15:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada","datePublished":"2020-11-12T13:15:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/"},"wordCount":443,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/","name":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=","datePublished":"2020-11-12T13:15:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDk4MSMzODIzMTU2IzIwODI1MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-announces-dosing-of-first-breast-cancer-patient-with-tomivosertib-in-combination-with-chemotherapy-through-a-grant-from-stand-up-to-cancer-su2c-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer\u00ae (SU2C) Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379649"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}